The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
IBM (NYSE: IBM), Acumen, Dovel Technologies and IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.
FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.
The indefinite delivery/indefinite quantity contracts have a five-year ordering period.
The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.
